Yoga and Cardiovascular Disease
Research on the beneficial clinical and therapeutic role in heart disease, stroke, peripheral artery disease, and diabetes.
Dr. Hongmei Zhang, Bruns Endowed Professor of Biostatistics and Director of Epidemiology, Biostatistics, and Environmental Health in the School of Public Health, is collaborating with Dr. Indranill Basu-Ray, a cardiologist, and Interventional Cardiac Electrophysiologist at the Department of Veterans Affairs (VA) and an affiliated Professor at the School of Public Health, University of Memphis, on critical projects in cardiovascular disease prevention and treatment.
Cardiovascular Disease is the largest killer on the planet. Over 877,500 Americans die of CVD—one-third of all deaths annually. These diseases also take an economic toll, costing our healthcare system $216 billion annually and causing $147 billion in lost productivity. In 2017, the estimated cost of diagnosed diabetes was $327 billion in medical expenses and lost productivity. The principal mechanism of death in Diabetes is CVD. One of every six dollars spent on health care costs is for CVD. Despite massive developments in technology using newer devices, interventional procedures, and drugs, the disease prevalence has not shown much of a decrease. This calls for out-of-the-box thinking, including initiating lifestyle changes as a public health policy to counter this epidemic. Yoga is the most popular form of integrative medicine used worldwide. While yoga is known to bring about drastic lifestyle changes, it also initiates processes in the body that reduce vascular inflammation, the root cause of CVD.
Zhang and Basu-Ray’s work will help to illuminate yoga’s clinical and therapeutic role in heart disease, stroke, peripheral artery disease, and diabetes. The initial focus is on the impact of yoga on major adverse cardiovascular events utilizing advanced statistical methods, including network meta-analyses, that will help understand the role of yoga in preventing and treating this surge of CVD both at a personal and community level. Further studies will elucidate the clinical significance of genetic, epigenetic, hormonal, and other mechanisms to attenuate CVD that yoga has been credited with.
With the expertise from both sides, the projects will establish a strong and potentially productive collaboration between the VA and UofM and offer great research opportunities to graduate and postgraduate students in the School of Public Health. The project would also likely contribute novel research on the clinical significance of yoga as a preventive and therapeutic entity for the largest killer on the planet.
For more information on this research, contact Zhang at [email protected].
DR INDRANILL BASU-RAY IN USA NEWS
Cardiac Contractility Modulation CCM is a brand new therapy that can help salvage heart failure patients with very poor prognosis. Dr. Basu-Ray and his team performed the first case of CCM in region and one of the early cases in the USA.
Chronic Heart failure is a common health problem with over 6.5 million suffering if not more. In the US, the annual direct cost of heart failure (HF) is estimated at over $30 billion, largely driven by the >1 million hospitalizations in which HF is the primary discharge diagnosis. Heart failure is currently treated with a slew of medication called Goal Directed Medical Therapy (GDMT) with many patient not being able to tolerate the medications or fails to improve on them. Approximately one third of these patients depending on the population studies are eligible for device therapy for heart failure commonly called Cardiac Resynchronization Therapy (CRT or BiV in short). Unfortunately CRT works in only 7 out of 10 heart failure patients implanted with it. Patient not responding to either GDMT and CRT (or those not a candidate for CRT) are thus not uncommon and as expected have a very poor prognosis. Untreated heart failure can have worse prognosis than many cancers.
Cardiac contractility modulation (CCM) is a state of art new device-based therapy for heart failure (HF) that involves applying relatively high-voltage (≈7.5 V), long-duration (≈20 milliseconds), biphasic electric signals to the right ventricular septal wall during the absolute myocardial refractory period. Accordingly, CCM signals do not elicit a new contraction; rather, they influence the biology of the failing myocardium. CCM signals have been shown to improve heart failure by improving Ejection Fraction(EF). Three-dimensional echocardiographic studies showed that CCM induces reverse LV remodeling and improves EF over time. CCM exerts a multitude of biochemical and molecular effects locally and remotely from the site of stimulation, including shifts of a large number of abnormally expressed genes toward normal, many of which involve pathways that regulate calcium cycling and myocardial contraction.
Texas Heart Institute, Baylor College of Medicine, Houston, TX
Tulane Heart and Vascular Institute New Orleans, LA
Massachusetts General Hospital, Harvard Medical School, Boston, MA
DR. Indranill Basu Ray
Name: Dr. Indranill Basu Ray
Profile: Consultant Cardiologist and Electrophysiologist
Email: [email protected]
He trained in Cardiology & Cardiac Electrophysiology from Tulane, Baylor College of Medicine. He trained in EP research from Massachusetts General Hospital. He was a former faculty at Beth Israel Deaconess Medical Center & Harvard Medical School & Tulane University Medical Center.
An Enlightening Encounter: Meeting Mahant Swami Maharaj at Akshardham BAPS Temple
Gave a talk to over 10000 devotees at the inauguration of the Akshardham BAPS Swaminatayan Temple at Robinsville, New Jersey. Blessed to have met & taken the blessings of Mahant Swami Maharaj (Swami Keshavjivandasji) is the sixth and present spiritual head of the organization & presented him a copy of the book The Principle & Practice of Yoga in Cardiovascular Medicine.
Letter from pm narendra modi